ArticleMetabolomics : Official journal of the Metabolomic Society2025
Volatile organic compound exposure is associated with hyperuricemia in the general population: an analysis of 6878 adults from the NHANES.
Article in Metabolomics : Official journal of the Metabolomic Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- A metabolomic signatures in hyperuricemia: a systematic review.Metabolomics : Official journal of the Metabolomic Society · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyperuricemia is clinically significant as the primary risk factor for gout and is strongly associated with cardiovascular diseases, hypertension, and chronic kidney disease. However, its relationship with exposure to volatile organic compounds (VOCs) remains unclear. This study explores the association between urinary VOC metabolite concentrations and the prevalence of hyperuricemia. RESEARCH DESIGN AND
methodsData from adults aged ≥ 18 years with at least one urinary VOC measurement were obtained from the 2011-2018 National Health and Nutrition Examination Survey (NHANES). Associations between sixteen urinary VOC metabolite levels and hyperuricemia were analyzed using univariate and multivariable logistic regression, adjusted for demographic and clinical covariates.
resultsData of a total of 6,878 participants were analyzed. Multivariable analysis revealed that, after adjusting for relevant confounders, there were significant associations between higher levels of certain urinary VOC metabolites and hyperuricemia. Specifically, as compared to the lowest level (tertile 1), higher levels (tertile 3) of BMA (aOR = 1.38), CEMA (aOR = 1.59), CYMA (aOR = 1.41), 3HPMA (aOR = 1.34), PGA (aOR = 1.41), HPMMA (aOR = 1.48), MA (aOR = 1.33), 2HPMA (aOR = 1.34), and DHBMA (aOR = 1.35) were significantly associated with increased odds of hyperuricemia.
conclusionsThe findings indicate that specific urinary VOC metabolites are independently associated with an increased likelihood of hyperuricemia. These findings provide a direction for future experimental studies to investigate the underlying mechanisms and confirm causal relationships.
Indexed as
Identifiers
40335851What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.